Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
ICMT Inhibitor
ICMT-IN-26 is a selective inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 value of 0.36 μM. This compound is utilized in biochemical research to investigate the role of ICMT in protein modification and signal transduction pathways. Its inhibition profile makes it a valuable tool for studying diseases associated with dysregulated protein methylation. -
ICMT Inhibitor
ICMT-IN-16 is a selective inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 value of 0.131 μM. This compound is utilized in research to elucidate the role of ICMT in protein modification and signal transduction pathways. Its inhibition can provide insights into various cellular processes, making it a valuable tool for studies focused on cancer biology and other related fields. -
ICMT Inhibitor
ICMT-IN-41 is a selective inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT) with an IC50 of 0.069 μM. This compound has demonstrated significant potential in regulating post-translational modifications of proteins, making it valuable for studies related to cell signaling and protein stability. It is particularly relevant in research focused on cancer biology and the roles of protein modification in disease pathways. -
ICMT Inhibitor
ICMT-IN-31 is a potent inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT) with an IC50 value of 0.0038 μM. This compound effectively disrupts protein farnesylation, influencing cellular processes such as signal transduction and protein localization. ICMT-IN-31 is particularly valuable for research in cancer biology and the study of post-translational modifications. -
ICMT Inhibitor
ICMT-IN-54 is an adamantyl analogue that functions as an inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT), exhibiting an IC50 value of 12.4 μM. This compound effectively inhibits the methylation of BFC (N-biotinyl-(6-aminohexanoic)-S-farnesyl-L-cysteine) in Saccharomyces cerevisiae expressing ICMT, thereby demonstrating its potential to interfere with ICMT-mediated methylation processes. ICMT-IN-54 is a valuable tool for research into the roles of ICMT in cellular signaling and protein modification. -
ICMT Inhibitor
ICMT-IN-18 is a potent inhibitor of isoprenylcysteine carboxymethyltransferase (ICMT), demonstrating an IC50 of 0.066 μM. This compound is valuable for investigating the role of ICMT in post-translational modifications and protein processing. Its applications extend to studies of cancer biology and signal transduction pathways where altered protein function may influence disease progression. -
ICMT Inhibitor
ICMT-IN-40 is a selective inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 value of 0.031 μM. This compound disrupts protein modification by inhibiting cysteine methylation, a critical process for the function and stability of various proteins involved in cellular signaling. ICMT-IN-40 is useful in research applications focused on studying protein prenylation and its implications in cancer and other diseases. -
ICMT Inhibitor
ICMT-IN-11 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 of 0.031 μM. This compound is valuable for research into protein post-translational modifications and their implications in various cellular processes. It is particularly useful in studies focused on cancer biology and signaling pathways involving prenylated proteins. -
ICMT Inhibitor
ICMT-IN-29 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 value of 0.019 μM. This compound exhibits significant inhibitory activity and can be utilized in research applications aimed at elucidating the role of ICMT in protein modification and cellular signaling pathways. Its ability to selectively inhibit ICMT makes it a valuable tool for studying the implications of isoprenylation in various biological contexts. -
ICMT Inhibitor
ICMT-IN-38 is a selective inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 value of 0.049 μM. This compound is valuable for investigating the role of ICMT in post-translational modifications and its implications in various biological processes. Research applications include studies on cancer biology and cellular signaling pathways, where modulation of ICMT activity may reveal novel therapeutic targets. -
ICMT Inhibitor
ICMT-IN-43 is a potent inhibitor of the isoprenylcysteine carboxyl methyltransferase (ICMT) enzyme, with an IC50 value of 0.04 μM. This compound is instrumental in studying the role of protein methylation in various cellular processes and signaling pathways. ICMT-IN-43 can be utilized in research focused on cancer biology, neurodegenerative diseases, and other pathologies linked to post-translational modifications. -
ICMT Inhibitor
ICMT-IN-39 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 of 0.031 μM. This compound effectively disrupts the methylation process of isoprenylated proteins, providing valuable insights into cellular signaling pathways. ICMT-IN-39 is applicable in research focused on the roles of protein modification in various diseases, including cancer and neurodegenerative disorders. -
ICMT Inhibitor
ICMT-IN-32 is a selective inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), showcasing an IC50 value of 0.777 μM. This compound is utilized in biochemical research to examine the role of ICMT in post-translational modifications of proteins. Its inhibitory properties make it valuable for studying signaling pathways and cellular processes related to protein farnesylation. -
ICMT Inhibitor
ICMT-IN-23 is a selective inhibitor of Isoprenylcysteine carboxylmethyltransferase (ICMT), exhibiting an IC50 value of 0.123 μM. This compound plays a crucial role in studying post-translational modifications involved in protein function and stability. ICMT-IN-23 is valuable for research applications focusing on signal transduction, protein interaction studies, and the development of novel therapeutic strategies targeting ICMT. -
ICMT Inhibitor
ICMT-IN-10 is a selective inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT), with an IC50 value of 0.184 μM. This compound effectively disrupts the methylation of isoprenylated proteins, thereby playing a critical role in various signaling pathways. ICMT-IN-10 is valuable for studying the biological implications of ICMT in cancer research and potentially in other diseases associated with aberrant protein methylation. -
ICMT Inhibitor
ICMT-IN-25 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 value of 0.025 μM. This compound is significant in biochemical research focused on post-translational modifications, particularly in the study of protein localization and function mediated by ICMT. Its application extends to the investigation of cancer biology and other diseases where ICMT plays a crucial role in regulating protein activity. -
ICMT Inhibitor
ICMT-IN-53 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 value of 0.96 μM. This compound demonstrates significant antiproliferative activity, effectively inhibiting the growth of MDA-MB-231 and PC3 cancer cell lines with IC50 values of 5.14 μM and 5.88 μM, respectively. ICMT-IN-53's PAMPA permeability makes it suitable for various biological research applications, particularly in the study of cancer cell proliferation and signaling pathways. -
ICMT Inhibitor
ICMT-IN-48 is a competitive inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT), with a Km of 13 μM for the prenylated methyl acceptor, the enzyme's initial substrate. This compound effectively inhibits ICMT activity, demonstrating IC50 values of 3.5 μM at 1×Km S-adenosylmethionine (SAM) and 2.3 μM at 10×Km SAM. ICMT-IN-48 is valuable for studying the role of ICMT in cellular signaling and post-translational regulation related to prenylated proteins in various biological systems. -
ICMT Inhibitor
ICMT-IN-45 is a selective inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 of 0.132 μM. This compound disrupts the post-translational modification of proteins, thereby influencing signaling pathways associated with cancer and other diseases. ICMT-IN-45 is useful in research applications aimed at understanding ICMT-related biological processes and evaluating the potential therapeutic effects of ICMT inhibition. -
ICMT Inhibitor
ICMT-IN-2 is a potent inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT), demonstrating an IC50 value of 0.168 μM. This compound effectively disrupts protein prenylation processes, making it a valuable tool for investigating the role of ICMT in various biological systems. ICMT-IN-2 has applications in studying signal transduction pathways and potential therapeutic interventions in diseases associated with aberrant protein modifications. -
ICMT Inhibitor
ICMT-IN-14 is a selective inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 value of 0.025 μM. This compound plays a critical role in the modulation of post-translational modifications of proteins associated with oncogenic signaling pathways. ICMT-IN-14 is ideal for research applications focused on protein methylation dynamics and the investigation of cancer biology. -
ICMT Inhibitor
ICMT-IN-47 is a specific inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 value of 0.76 μM. This compound effectively disrupts ICMT activity, which is critical in the post-translational modification of proteins involved in various signaling pathways. ICMT-IN-47 can be utilized in research applications focused on cancer biology, signaling mechanisms, and studies targeting prenylated proteins. -
ICMT Inhibitor
ICMT-IN-19 is a specific inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT), demonstrating an IC50 value of 0.026 μM. This compound effectively blocks ICMT activity, impacting post-translational modifications of proteins that can influence various cellular processes. ICMT-IN-19 is suitable for research applications focusing on protein processing, signal transduction, and cancer biology. -
ICMT Inhibitor
ICMT-IN-22 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 value of 0.63 μM. This compound is instrumental in research applications related to lipid modification pathways, playing a crucial role in understanding post-translational modifications of proteins. Its use can facilitate studies on cellular signaling, protein stability, and the implications of ICMT activity in various diseases. -
ICMT Inhibitor
ICMT-IN-49 is a potent inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT), demonstrating an IC50 of 0.12 μM. This compound plays a critical role in modulating cellular processes by regulating protein methylation and is valuable in studies targeting protein function and signaling pathways. Research applications include investigations into cancer biology, neurodegenerative diseases, and other conditions where ICMT activity is implicated. -
ICMT Inhibitor
ICMT-IN-42 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), demonstrating an IC50 value of 0.054 μM. This compound is valuable for research into the role of ICMT in post-translational modifications and protein function regulation. It is suitable for studies investigating cancer biology, signal transduction, and therapeutic development targeting ICMT pathways. -
ICMT Inhibitor
ICMT-IN-9 is an inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 of 0.16 μM. This compound selectively targets ICMT, playing a significant role in regulating post-translational modifications of proteins that are essential for various cellular processes. ICMT-IN-9 can be utilized in research applications focused on cancer biology, signal transduction, and the study of protein interactions influenced by methylation. -
ICMT Inhibitor
ICMT-IN-3 is a potent inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT) with an IC50 value of 0.015 μM. This compound is crucial for studying protein modification processes, particularly in the context of signal transduction and cellular regulation. It serves as a valuable tool for investigating the role of ICMT in various biological pathways and its potential implications in disease mechanisms. -
ICMT Inhibitor
ICMT-IN-4 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 value of 0.27 μM. This compound plays a crucial role in the modulation of protein prenylation, impacting various cellular processes. It is valuable for research applications aimed at investigating the role of ICMT in signaling pathways and disease models related to cancer and other disorders. -
ICMT Inhibitor
ICMT-IN-33 is a potent inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT) with an IC50 value of 0.46 μM. This compound effectively disrupts the post-translational modification of proteins by inhibiting ICMT activity. It is invaluable for research applications focused on elucidating the role of ICMT in cellular signaling and protein function, as well as potential therapeutic interventions targeting ICMT-related pathways. -
ICMT Inhibitor
Farnesylcysteine (FC) is a competitive inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT). It has been shown to induce an abscisic acid (ABA) hypersensitive phenotype in Arabidopsis thaliana, highlighting its role in plant stress responses. This reagent is valuable for research applications focused on signaling pathways and mechanisms involving ICMT inhibition and ABA-related processes. -
ICMT Inhibitor
ICMT-IN-55 is a selective inhibitor of isoprenylcysteine carboxymethyltransferase (ICMT) with an IC50 of 90 nM. This compound plays a crucial role in inhibiting ICMT activity, leading to the disruption of protein processing involved in various cellular signaling pathways. ICMT-IN-55 is utilized in research focused on understanding the biological significance of protein lipidation and its implications in cancer and other diseases. -
ICMT Inhibitor
Spermatinamine is a natural inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT). This novel alkaloid, characterized by its bromotyrosyl-spermine-bromotyrosyl sequence, exhibits significant biological activity affecting protein prenylation. It is derived from the Australian sponge Pseudoceratina and is useful in research applications investigating the roles of ICMT and protein modification pathways in cellular processes. -
ICMT Inhibitor
CAY10677 is a potent inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT), a critical enzyme involved in post-translational modifications of proteins. This compound has demonstrated significant ability to inhibit cancer cell proliferation, making it a valuable tool for cancer research. Additionally, CAY10677 exhibits favorable PAMPA permeability, enhancing its applicability in cellular assays. -
ICMT Inhibitor
UCM-13207 is a selective inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT) with potential applications in aging research. This compound has been shown to mitigate progeria-like characteristics and enhance the survival rate in LmnaG609G/G609G mice, serving as an effective tool in studying cellular aging processes and related disorders. Researchers can utilize UCM-13207 to explore therapeutic strategies for age-related diseases. -
ICMT Inhibitor
J1-1 is an inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT), with an IC50 of 1.0 μM. This compound demonstrates notable anticancer activity, making it a valuable tool for research into cancer biology. J1-1 can be utilized in studies focusing on protein modification and its implications in oncogenic signaling pathways. -
LTB4 inhibitor
U-75302 is a potent inhibitor of leukotriene B4, developed as a pyridine analogue. This compound demonstrates significant anti-inflammatory activity, making it valuable for research into various inflammatory diseases. U-75302 can help elucidate the role of leukotriene B4 in pathophysiological processes, contributing to better understanding and potential therapeutic strategies in inflammation-related conditions. -
PGF2α/LTB4 Inhibitor
Darbufelone is a dual inhibitor of prostaglandin F2α (PGF2α) and leukotriene B4 (LTB4) production, primarily targeting the cyclooxygenase enzyme PGHS-2 with an IC50 of 0.19 μM, while showing markedly lower potency against PGHS-1 (IC50 of 20 μM). This compound is valuable for research focused on inflammation, pain modulation, and the role of eicosanoids in various pathological conditions. Its selective inhibition of PGF2α and LTB4 makes Darbufelone a useful tool for studying the intersection of these signaling pathways in cellular responses. -
FPR Inhibitor
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) acts as an inhibitor of N-formyl peptide receptors (FPR). This compound effectively reduces FMLP-induced release of peptide leukotrienes and disrupts the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids in a three-dimensional fibrin gel model, which simulates the conditions associated with proliferative diabetic retinopathy (PDR) and vascular endothelial growth factor (VEGF). Additionally, Boc-Phe-Leu-Phe-Leu-Phe counteracts the anti-inflammatory and antifibrotic effects of Ac2-26. It is suitable for applications in immunological research. -
LTB4 Inhibitor
Halometasone is a corticosteroid that functions as an inhibitor of leukotriene B4 (LTB4) synthesis. It exhibits anti-inflammatory properties by reducing LTB4 and thymic stromal lymphopoietin (TSLP) levels. Halometasone is widely utilized in research related to psoriasis and other eczematous skin disorders, providing insights into corticosteroid-mediated effects on inflammatory pathways. -
Leukotriene Synthesis Inhibitor
L-674573 is a quinoline compound that functions as a selective inhibitor of leukotriene synthesis. It effectively inhibits leukotriene production induced by Calcimycin and N-Formyl-Met-Leu-Phe, with IC50 values of 100 nM and 50 nM, respectively. L-674573 specifically targets and inhibits the translocation of 5-lipoxygenase, making it a valuable tool for research into inflammatory processes and leukotriene-related diseases. Its application is particularly relevant in studies aimed at understanding leukotriene signaling pathways and developing anti-inflammatory therapeutics. -
Leukotriene Inhibitor
Piriprost potassium is a potent leukotriene synthesis inhibitor. It effectively suppresses the release of leukotrienes and histamine in isolated porcine lung cells, exhibiting an IC50 of 0.11 μM. Additionally, Piriprost potassium enhances alkaline phosphatase (ALP) activity in cultured endometrial stromal cells, making it a useful tool for research in inflammation and reproductive biology. -
Leukotriene Formation Inhibitor
Pirodomast is a potent leukotriene formation inhibitor that targets the release of leukotriene D4 (LTD4) and thromboxane B2 in anaphylactic guinea pig lung tissues. With IC50 values of 3.9 μM for LTD4 and 1.9 μM for thromboxane B2, Pirodomast demonstrates significant inhibitory activity. This compound is valuable for research applications related to asthma and inflammatory responses, providing insights into leukotriene-mediated pathways in respiratory conditions. -
cPLA2α Inhibitor
ZPL-5212372 is a potent inhibitor of cytosolic phospholipase A2 alpha (cPLA2α) with an IC50 of 7 nM. This compound efficiently reduces the release of key inflammatory mediators such as prostaglandin D2, cysteinyl leukotrienes, leukotriene B4, and thromboxane A2 from human lung cells. Research indicates that ZPL-5212372 effectively attenuates delayed bronchoconstriction and airway hyperresponsiveness in models of allergic inflammation. Consequently, it serves as a valuable tool for investigating mechanisms and potential therapies for asthma. -
Dual Enkephalinase Inhibitor
PL265 is a dual enkephalinase inhibitor that acts as a prodrug of PL254. It effectively inhibits both neutral endopeptidase (neprilysin) and aminopeptidase N, leading to increased local concentrations of enkephalins like Met-Enkephalin and Leu-Enkephalin. This action subsequently activates μ and δ opioid receptors, resulting in a potent analgesic effect. Additionally, PL265's inhibition of leukotriene A4 hydrolase (LTA4H) may further enhance its anti-inflammatory properties by reducing the production of leukotriene B4 (LTB4). This reagent is particularly valuable in non-addictive chronic pain research. -
5-1ipoxygenase Inhibitor/Leukotriene D4 Antagonist
WAY-126299A is an orally active dual inhibitor of 5-lipoxygenase, demonstrating an IC50 of 12.2 μM, and serves as a leukotriene D4 antagonist with a pKB of 6.4. This compound effectively inhibits antigen-induced leukotriene-dependent bronchoconstriction. WAY-126299A is valuable in research related to asthma and other inflammatory conditions where leukotriene signaling plays a critical role. -
LTE4 Inhibitor
LY 245769 is a leukotriene E4 (LTE4) inhibitor that functions as an omega-trifluoro analog. It exhibits inhibitory activity by interfering with the omega-oxidation of N-acetyl-LTE4 and leukotriene B4 (LTB4), with an IC50 value of 4 μM. This compound is essential for research on inflammatory processes and bronchoconstriction, contributing to the understanding of leukotriene signaling pathways and their role in respiratory diseases. -
MRP1 Inhibitor
LY329146 is a selective inhibitor of multidrug resistance protein 1 (MRP1). It effectively inhibits the transport of leukotriene C4 (LTC4) with an IC50 of 0.8 μM. This compound is valuable for studies exploring multidrug resistance mechanisms and may have applications in enhancing the efficacy of chemotherapy in resistant cancer cells. -
Leukotriene Receptor Inhibitor
12(S)-HEPE is a monohydroxy fatty acid that acts as a leukotriene receptor inhibitor. It is synthesized from eicosapentaenoic acid (EPA) through the action of 12-lipoxygenase (12-LO). In unstimulated neutrophils, 12(S)-HEPE is metabolized to 12(S),20-diHEPE, while stimulated neutrophils generate 5(S),12(S)-HEPE via the 5-lipoxygenase pathway. Its competitive inhibition of arachidonic acid as a substrate for 5-lipoxygenase in leukotriene formation supports its potential anti-inflammatory effects associated with omega-3 fatty acids. -
LTA4H Inhibitor
JNJ-40929837 is a selective and orally active inhibitor of leukotriene A4 hydrolase (LTA4H). This compound effectively inhibits aminopeptidase activity, resulting in the accumulation of Pro-Gly-Pro in serum. JNJ-40929837 is primarily utilized in asthma research to explore its potential therapeutic effects and mechanisms of action related to inflammatory responses.
